Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Date:5/21/2008

vels of Trp-p8 compared to the normal prostates. In comparing untreated BPH-induced prostates to those treated with D-3263, treatment with D-3263 resulted in a 39 percent reduction in prostate weight compared to control (p=0.004). In addition, treatment with D-3263 resulted in a 98 percent reduction (2221.2 pg/ml versus 43.1 pg/ml) in plasma dihydrotestosterone (DHT) levels (p=0.004) suggesting D-3263 is affecting androgen metabolism, which is a known stimulant for BPH and prostate cancer. These effects were seen in a dose-dependent manner, achieving efficacy comparable to finasteride. Histopathological examination post treatment with D-3263 indicated that reduction of prostate size and weight was due to a return to normalcy. Changes in Trp-p8 expression and plasma DHT levels correlated with both efficacy and dose.

About Trp-p8

Trp-p8 (also known as Trp-M8) was identified through Dendreon's in-house discovery efforts. It is an ion channel that is triggered by cold temperatures and small-molecule agonists. In normal human tissues Trp-p8 is expressed predominantly in the prostate where it is over-expressed in BPH and prostate cancer, as well as a range of other cancers including breast, lung and colon. Dendreon has synthesized bioavailable small molecule agonists that activate the Trp-p8 ion channel and induce cell death. The lead molecule, D-3263, is undergoing preclinical evaluation in anticipation of an investigational new drug application to be filed with the U.S. Food and Drug Administration for clinical evaluation in cancer patients.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response.
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
5. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Napo Presents at ISPOR Meeting in Toronto
8. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
9. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in Boston.  The public is welcome to ... the Array BioPharma website.Event: Wells Fargo Securities Healthcare ... September 10, 2015Time:  , 10:20 a.m. Eastern Time ...
(Date:9/2/2015)... 2, 2015 About Chronic Lymphocytic Leukemia ... characterized by increased production of lymphocytes. It has been ... it can spread to other parts of the body. ... of the slow buildup of the cancerous cells. During ... the spleen, liver, and lymph nodes. The course of ...
(Date:9/2/2015)... STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye, today announced that its Board of Directors has ... Mr. Wall was formerly the General Counsel ... firm, for more than nine years. Mr. Wall is currently ... the Corporate Governance Committee and member of the Audit Committee, ...
Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
... Md., Nov. 28, 2011 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today that ... present at the Piper Jaffray 23rd Annual Healthcare Conference ... Richman will also be available to participate in one-on-one ...
... Conn., Nov. 28, 2011 Gaylord Sleep Medicine now ... their Glastonbury, Guilford, North Haven and Trumbull locations. ... new Sleep Apnea Management program has expanded to offer ... patient needs. Originally designed to improve PAP compliance, the ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2Gaylord Sleep Medicine Expands Sleep Apnea Management Program 2
(Date:9/3/2015)... WI (PRWEB) , ... September 03, 2015 , ... At ... after becoming dissatisfied with the traditional health care model, where the primary care physician ... of individuals who want to become educated about their health issues and empowered to ...
(Date:9/3/2015)... ... 2015 , ... James Earl Jones will be hosting an upcoming VOICES IN ... Jones will introduce a segment that discusses why it is important for the workplace ... be fostered in any working environment. , Employers are out billions of dollars year ...
(Date:9/3/2015)... ... September 03, 2015 , ... Fashion designer Kim (29 ... of the most recent episode of the hit ABC series “Extreme Weight Loss” ... image of her industry. She provided herself with the motivation to transform when she ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... by the Military Officers Association of America (MOAA) and Wounded Warrior Project® ... Caring For Our Own,” expert panelists will lead interactive discussions on the ...
Breaking Medicine News(10 mins):Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3
... , DES MOINES, Iowa, July 10 The "Help is ... the week of July 13 - 16 at various cities ... on programs that provide prescription medicines for free or nearly ... compared to 3.7 percent a year ago, the Partnership for ...
... , NEW YORK, July 10, 2009 Forest ... its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, ... that they have entered into a settlement ... a reference that includes its 100% subsidiaries) and ...
... Va., July 10 The American Physical Therapy Association (APTA) is ... to be properly assessed and fitted by a physical therapist to ... published in the Journal of the American Geriatrics Society ... emergency rooms each year due to falls from improper use and ...
... DENVER, July 10 Cochlear Americas announced today that ... the Cochlear(TM) Baha(R) BP100 Sound Processor, the industry,s first ... an excellent choice for many children and adults with ... deafness. , , The Baha BP100 improves ...
... , , , SOUTH SAN FRANCISCO, Calif., ... scientific presentations at the International Society on Thrombosis and ... its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor ... oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, ...
... damage during play, study finds , FRIDAY, July 10 ... before the season starts may predict the player,s chance ... , Such knowledge could help the pitcher avert ... said. , A five-year study of 144 professional baseball ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Iowa Workers Hurt by Recession 4Health News:Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation 2Health News:Physical Therapists Say Proper Fit and Use of Walkers and Canes Can Prevent Fall-Related Injuries in Elderly 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 2Health News:Cochlear Americas Announces FDA Clearance of the Cochlear(TM) Baha(R) BP100 Sound Processor, the Industry's First Programmable Bone Conduction Hearing Solution 3Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Rad-9™...
The Avant® 9700 combines flexible alarm options, unparalleled non-volatile memory, and Nonins time-honored technology to give you an easy-to-use and efficient monitor....
Halogen-free immersion oil based on ester oil....
Medicine Products: